Gene:
ABCG2
ATP-binding cassette, sub-family G (WHITE), member 2

Overview

Alternate Names: ABC transporter; ATP-BINDING CASSETTE TRANSPORTER, PLACENTA-SPECIFIC; ABCP; ATP-BINDING CASSETTE, SUBFAMILY G, MEMBER 2; ABCG2; ATP-binding cassette sub-family G (WHITE) member 2; ATP-binding cassette transporter G2; ATP-binding cassette, sub-family G, member 2; BREAST CANCER RESISTANCE PROTEIN; BCRP; breast cancer resistance protein; mitoxantrone resistance protein; placenta specific MDR protein
Alternate Symbols: ABC15; ABCG2; ABCP; AF103796.1; BCRP; BCRP1; BMDP; CD338; CDw338; EST157481; MGC102821; MRX; MXR; MXR1
PharmGKB Accession Id: PA390

Details

Cytogenetic Location: chr4 : q22.1
GP mRNA Boundary: chr4 : 89230440 - 89299035
GP Gene Boundary: chr4 : 89227440 - 89309035
Strand: minus
Product Name: ABC transporter, ATP-binding cassette sub-family G (WHITE) member 2, ATP-binding cassette transporter G2, ATP-binding cassette, sub-family G, member 2, breast cancer resistance protein, mitoxantrone resistance protein, placenta specific MDR protein
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Curated Annotations (Curated Annotation)

  1. rs13120400 at chr4:89252551 in ABCG2
    SNP is associated with clinical reponse to methotrexate in patients with psoriasis.
    Related Drugs:
    methotrexate
    Related Diseases:
    Psoriasis
    Evidence:
    PMID:18256692
  2. rs2231142 at chr4:89271347 in ABCG2
    Lung cancer patients carrying the A allele of ABCG2:421C>A were at increased risk for diarrhea but not skin toxicity following oral gefitinib treatment.
    Variant Name:
    ABCG2:421C>A; ABCG2:Q141K; rs2231142
    Related Drugs:
    gefitinib
    Related Diseases:
    Carcinoma, Non-Small-Cell Lung, Diarrhea, Lung Neoplasms
    Evidence:
    PMID:17148776
  3. rs2231142 at chr4:89271347 in ABCG2
    The ABCG2 421C>A genotype significantly affected the pharmacokinetics of diflomotecan in 5 patients heterozygous for this allele.
    Variant Name:
    ABCG2:421C>A; ABCG2:Q141K; rs2231142
    Related Drugs:
    diflomotecan
    Related Diseases:
    Neoplasms
    Evidence:
    PMID:15229462
  4. rs2231142 at chr4:89271347 in ABCG2
    A allele is associated with increased rosuvastatin plasma AUC
    Variant Name:
    ABCG2:421C>A
    Related Drugs:
    rosuvastatin
    Evidence:
    PMID:19474787
  5. rs2231142 at chr4:89271347 in ABCG2
    Introduction of the mutation Q141K in the ABCG2 gene by site-directed mutagenesis resulted in 53% reduced urate transport rates compared to wild-type ABCG2 (P < 0.001). Data of this study indicate that at least 10% of all gout cases in whites are attributable to this causal variant.
    Variant Name:
    ABCG2: Q141K
    Related Diseases:
    Gout
    Evidence:
    PMID:19506252
  6. rs2231142 at chr4:89271347 in ABCG2
    studied allele=A; study size=46 (30 children; 16 adults);PK=significantly lower clearance (-23%) of imatinib and major metabolite in heterozygous versus wild-type homozygous patients when genotype considered with body weight, albuminemia and alpha1-acid glycoprotein covariates; significance= P < 0.05; genotype alone not associated with increased clearance
    Variant Name:
    ABCG2:421C>A; ABCG2:Q141K;
    Related Drugs:
    imatinib
    Evidence:
    PMID:18981009
  7. rs2231142 at chr4:89271347 in ABCG2
    study size=14, only SLCO1B1 521TT and CYP2C9*1/*1 wild-type homozygotes . ethnicity=Japanese. PK and signficance= AUC of rosuvastatin were lower in the 421CC group than in the 421CA+421AA group P=0.018; C(max) value was higher in the 421CA+421AA group than that in the 421CC group P=0.048; CL/F was lower in the 421CA+421AA group than that in the 421CC group P=0.043). The T(1/2) and T(max) values showed no difference between 421CC vs 421CA+421AA
    Variant Name:
    ABCG2:421C>A; ABCG2:Q141K;
    Related Drugs:
    rosuvastatin
    Evidence:
    PMID:16784736
  8. rs2231142 at chr4:89271347 in ABCG2
    control size=7; K141 cases=6; PK=in healthy subjects, disposition of lamivudine was not significantly influenced by known functional variants
    Variant Name:
    ABCG2:421C>A; ABCG2:Q141K;
    Related Drugs:
    lamivudine
    Evidence:
    PMID:17509035
  9. rs72552713 at chr4:89271981 in ABCG2
    control size=7; X126 cases=6; PK=in healthy subjects, disposition of lamivudine was not significantly influenced by known functional variants
    Variant Name:
    ABCG2:Q126X
    Related Drugs:
    lamivudine
    Evidence:
    PMID:17509035
  10. rs17731538 at chr4:89274403 in ABCG2
    SNP is associated with clinical reponse to methotrexate in patients with psoriasis.
    Related Drugs:
    methotrexate
    Related Diseases:
    Psoriasis
    Evidence:
    PMID:18256692
  11. rs2231137 at chr4:89280138 in ABCG2
    control size=7; M12 cases=6; PK=in healthy subjects, disposition of lamivudine was not significantly influenced by known functional variants
    Variant Name:
    ABCG2:V12M
    Related Drugs:
    lamivudine
    Evidence:
    PMID:17509035

Non-Curated Annotations (Non-Curated Annotation)

  1. rs2231142 at chr4:89271347 in ABCG2
    GWAS results: Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. (Initial Sample Size: 11,847 individuals; Replication Sample Size: 14,867 individuals); (Region: 4q22.1; Reported Gene(s): ABCG2; Risk Allele: rs2231142-?); (p-value= 3E-60).This variant is associated with Serum urate.
    Evidence:
    PMID:18834626
    http://www.genome.gov/gwastudies/
  2. rs2231142 at chr4:89271347 in ABCG2
    Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. (Initial Sample Size: 11,847 individuals; Replication Sample Size: 14,867 individuals); (Region: 4q22.1; Reported Gene: ABCG2; Risk Allele: rs2231142-?) This variant is associated with Serum urate.
    Evidence:
    PMID:18834626
    http://www.genome.gov/gwastudies/
Variant names are different names that have been used in the literature and other resources to refer to the same variant. Non-curated variant information is accumulated solely by computational methods and has not been verified by the scientific staff at PharmGKB.

Non-Curated Information

A list of non-curated publications that mention this gene along with other genes is available.

Curated Information

The following drugs are in curated knowledge about this gene.

  Drug Class Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
antineoplastic agents
  •   
  • PD
  • PK
  •   
  • GN
Publications, Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
hmg coa reductase inhibitors
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
xenobiotics
  •   
  •   
  •   
  • FA
  • GN
Publications
  Drug Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
atorvastatin
  •   
  •   
  • PK
  •   
  • GN
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
capecitabine
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
carbamazepine
  •   
  • PD
  • PK
  • FA
  •   
Publications
Phenotype data available No genotype data Literature annotations available Not annotated
carboplatin
  • CO
  •   
  •   
  •   
  • GN
Publications
Phenotype data available No genotype data Literature annotations available Not annotated
cisplatin
  • CO
  • PD
  • PK
  • FA
  •   
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
cyanocobalamin
  •   
  • PD
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
cyclophosphamide
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
cyclosporine
  •   
  •   
  • PK
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
cytarabine
  • CO
  •   
  •   
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
daunorubicin
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
diflomotecan
  •   
  •   
  • PK
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
digoxin
  •   
  •   
  •   
  • FA
  •   
Publications
No phenotype data No genotype data No literature annotations Not annotated
dimethyl sulfoxide
  •   
  • PD
  • PK
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
docetaxel
  • CO
  • PD
  • PK
  •   
  • GN
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
doxorubicin
  • CO
  • PD
  • PK
  • FA
  • GN
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
erlotinib
  •   
  •   
  • PK
  • FA
  • GN
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
estramustine
  • CO
  •   
  •   
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
etoposide
  • CO
  •   
  •   
  •   
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
fluorouracil
  •   
  •   
  • PK
  • FA
  •   
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
fluvastatin
  •   
  •   
  • PK
  •   
  • GN
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
folic acid
  •   
  • PD
  • PK
  • FA
  • GN
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
gefitinib
  •   
  • PD
  • PK
  • FA
  • GN
Publications, Pathways, Variants
Phenotype data available Genotype Data Available Literature annotations available Not annotated
gemcitabine
  •   
  •   
  •   
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
imatinib
  • CO
  •   
  • PK
  • FA
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
irinotecan
  •   
  • PD
  • PK
  • FA
  • GN
Publications, Pathways
Phenotype data available No genotype data Literature annotations available Not annotated
leucovorin
  •   
  • PD
  • PK
  • FA
  • GN
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
lovastatin
  •   
  •   
  • PK
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
methotrexate
  • CO
  • PD
  • PK
  • FA
  • GN
Publications, Pathways, Variants
No phenotype data No genotype data Literature annotations available Not annotated
mitoxantrone
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
oxaliplatin
  •   
  • PD
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
paclitaxel
  • CO
  • PD
  • PK
  • FA
  • GN
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
pitavastatin
  •   
  •   
  • PK
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
platinum
  •   
  • PD
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
pravastatin
  •   
  •   
  • PK
  •   
  • GN
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
pyridoxine
  •   
  • PD
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
rosuvastatin
  •   
  •   
  • PK
  •   
  • GN
Publications, Pathways, Variants
Phenotype data available No genotype data Literature annotations available Not annotated
simvastatin
  •   
  •   
  • PK
  •   
  • GN
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
sirolimus
  •   
  •   
  • PK
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
sulfasalazine
  •   
  •   
  • PK
  • FA
  • GN
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
tacrolimus
  •   
  •   
  • PK
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
tegafur
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
topotecan
  •   
  •   
  • PK
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
valproic acid
  •   
  •   
  • PK
  •   
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
vincristine
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
vinorelbine
  • CO
  •   
  •   
  •   
  • GN
Publications

Non-Curated Information

A list of non-curated publications that mention this gene along with other drugs is available.

Curated Information

The following diseases are in curated knowledge about this gene.

  Disease Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
Adenocarcinoma
  •   
  • PD
  •   
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Arthritis, Rheumatoid
  •   
  • PD
  • PK
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Brain Neoplasms
  •   
  • PD
  •   
  • FA
  •   
Publications
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Breast Neoplasms
  • CO
  • PD
  • PK
  • FA
  • GN
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Carcinoma, Basal Cell
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Carcinoma, Non-Small-Cell Lung
  •   
  • PD
  • PK
  • FA
  • GN
Publications, Pathways, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Cardiomyopathy, Dilated
  •   
  • PD
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Cardiomyopathy, Hypertrophic
  •   
  • PD
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data No literature annotations Not annotated
Cardiomyopathy, Restrictive
  •   
  • PD
  • PK
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Cardiovascular Diseases
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data No literature annotations Not annotated
Chagas Cardiomyopathy
  •   
  • PD
  • PK
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Colonic Neoplasms
  •   
  • PD
  •   
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Colorectal Neoplasms
  •   
  • PD
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Diarrhea
  •   
  •   
  • PK
  •   
  •   
Pathways, Variants
No phenotype data No genotype data No literature annotations Not annotated
Gallbladder Neoplasms
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Gastrointestinal Neoplasms
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Gout
  •   
  •   
  •   
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Head and Neck Neoplasms
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Hypercholesterolemia
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Hyperlipidemias
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Hyperlipoproteinemia Type II
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Hypoxia-Ischemia, Brain
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • CO
  •   
  •   
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Leukemia, Myeloid, Acute
  • CO
  •   
  • PK
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Liver Neoplasms
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Lung Diseases
  • CO
  •   
  •   
  •   
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Lung Neoplasms
  •   
  • PD
  • PK
  • FA
  • GN
Publications, Pathways, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Lymphoma
  •   
  • PD
  •   
  • FA
  •   
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Melanoma
  •   
  • PD
  • PK
  • FA
  •   
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Muscular Diseases
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Myalgia unspecified
  •   
  •   
  • PK
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Myocardial Infarction
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Myositis
  •   
  •   
  • PK
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Neoplasms
  •   
  • PD
  • PK
  • FA
  • GN
Publications, Pathways, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Neurotoxicity Syndromes
  • CO
  •   
  •   
  •   
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Neutropenia
  •   
  • PD
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Ovarian Neoplasms
  •   
  • PD
  • PK
  • FA
  •   
Publications, Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Pancreatic Neoplasms
  •   
  •   
  • PK
  •   
  •   
Pathways
Phenotype data available Genotype Data Available Literature annotations available Not annotated
Precursor Cell Lymphoblastic Leukemia-Lymphoma
  •   
  • PD
  • PK
  • FA
  • GN
Publications, Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Prostatic Neoplasms
  • CO
  • PD
  •   
  • FA
  • GN
Publications
No phenotype data No genotype data Literature annotations available Not annotated
Psoriasis
  • CO
  • PD
  • PK
  •   
  • GN
Publications, Variants
No phenotype data No genotype data Literature annotations available Not annotated
Rhabdomyolysis
  •   
  •   
  • PK
  •   
  •   
Pathways
No phenotype data No genotype data Literature annotations available Not annotated
Stomach Neoplasms
  •   
  •   
  • PK
  •   
  •   
Pathways

Non-Curated Information

A list of non-curated publications that mention this gene along with other diseases is available.

Curated Phenotype Datasets

These datasets are sorted alphabetically by title.

Additional Datasets

These datasets are minimally curated and are sorted alphabetically by title.

  1. Association of BCRP/ABCG2 Phenotypes and Novel promoter and intron 1 SNPs
  2. PHARMACOKINETICS OF ERLOTINIB and ERLOTINIB induced TOXICITY

Downloads

You must sign in before you can download data.

LinkOuts

Ref Seq NT Accession:
AC_000047
AC_000136
NC_000004
NT_016354
NW_001838915
NW_922162
UniProtKB Accesssion:
ABCG2_HUMAN (Q9UNQ0)
Ensembl ID:
ENSG00000118777
GenAtlas ID:
ABCG2
GeneCard ID:
ABCG2
SOURCE ID:
ABCG2
MutDB ID:
ABCG2
PromoLign ID:
ortho_1903
HuGE ID:
ABCG2
Comparative Toxicogenomics Acc ID:
9429
ModBase:
Q8IX16

Common Searches

Non-Curated Publications

A list of non-curated publications that mention this gene is available.

The PharmGKB is financially supported by the NIH/ NIGMS and is managed at Stanford University (U01GM61374).
©2001-2010 PharmGKB.